262 related articles for article (PubMed ID: 33428178)
1. Opicapone: A Review in Parkinson's Disease.
Scott LJ
CNS Drugs; 2021 Jan; 35(1):121-131. PubMed ID: 33428178
[TBL] [Abstract][Full Text] [Related]
2. Opicapone: A Review in Parkinson's Disease.
Scott LJ
Drugs; 2016 Sep; 76(13):1293-1300. PubMed ID: 27498199
[TBL] [Abstract][Full Text] [Related]
3. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P;
Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
[TBL] [Abstract][Full Text] [Related]
4. The preclinical discovery and development of opicapone for the treatment of Parkinson's disease.
Ettcheto M; Busquets O; Sánchez-Lopez E; Cano A; Manzine PR; Verdaguer E; Olloquequi J; Auladell C; Folch J; Camins A
Expert Opin Drug Discov; 2020 Sep; 15(9):993-1004. PubMed ID: 32450711
[TBL] [Abstract][Full Text] [Related]
5. Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA.
Lees AJ; Ferreira J; Rascol O; Reichmann H; Stocchi F; Tolosa E; Poewe W
Expert Rev Neurother; 2017 Jul; 17(7):649-659. PubMed ID: 28580819
[TBL] [Abstract][Full Text] [Related]
6. The launch of opicapone for Parkinson's disease: negatives versus positives.
Castro Caldas A; Teodoro T; Ferreira JJ
Expert Opin Drug Saf; 2018 Mar; 17(3):331-337. PubMed ID: 29415596
[TBL] [Abstract][Full Text] [Related]
7. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.
Rocha JF; Falcão A; Santos A; Pinto R; Lopes N; Nunes T; Wright LC; Vaz-da-Silva M; Soares-da-Silva P
Eur J Clin Pharmacol; 2014 Sep; 70(9):1059-71. PubMed ID: 24925090
[TBL] [Abstract][Full Text] [Related]
8. Opicapone to Treat Early Wearing-off in Parkinson's Disease Patients: The Korean ADOPTION Trial.
Lee JY; Ma HI; Ferreira JJ; Rocha JF; Sung YH; Song IU; Ahn TB; Kwon DY; Cheon SM; Kim JM; Lee CS; Lee PH; Park JH; Lee JH; Park MY; Kim SJ; Baik JS; Choi SM; Shin HW; Lee HW; Kang SY; Jeon B
Mov Disord Clin Pract; 2024 Jun; 11(6):655-665. PubMed ID: 38594812
[TBL] [Abstract][Full Text] [Related]
9. [Opicapone for the treatment of Parkinson's disease: real-life data in Spain].
López-Ariztegui N; Mata-Alvarez Santullano M; Tegel I; Almeida F; Sarasa P; Rojo R; Rico-Villademoros F; Abril-Jaramillo J; Bermejo P; Borrue C; Caballol N; Campins-Romeu M; Clavero P; García-Caldentey J; Gómez-Mayordomo V; Labandeira C; Martí-Andrés G; Martínez-Castrillo JC; Martinez-Poles J; Muñoz T; Salom JM; Valderrama-Martín C; Vinagre-Aragón A
Rev Neurol; 2021 Dec; 73(s02):S01-S14. PubMed ID: 34897643
[TBL] [Abstract][Full Text] [Related]
10. Safety Profile of Opicapone in the Management of Parkinson's Disease.
Lees A; Ferreira JJ; Rocha JF; Rascol O; Poewe W; Gama H; Soares-da-Silva P
J Parkinsons Dis; 2019; 9(4):733-740. PubMed ID: 31498127
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic drug evaluation of opicapone for the treatment of Parkinson's disease.
Svetel M; Tomić A; Kresojević N; Kostić V
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):353-360. PubMed ID: 29345156
[TBL] [Abstract][Full Text] [Related]
12. Optimized clinical management of Parkinson's disease with opicapone. Recommendations from Spanish experts.
Linazasoro-Cristóbal G; López Del Val LJ; García Ruiz-Espiga P; López-Manzanares L; Luquin-Piudo MR; Martínez-Castrillo JC; Mir P; Pagonabarraga-Mora J
Rev Neurol; 2020 Jun; 70(s01):S1-S11. PubMed ID: 32515486
[TBL] [Abstract][Full Text] [Related]
13. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.
Ferreira JJ; Rocha JF; Falcão A; Santos A; Pinto R; Nunes T; Soares-da-Silva P
Eur J Neurol; 2015 May; 22(5):815-25, e56. PubMed ID: 25649051
[TBL] [Abstract][Full Text] [Related]
14. Opicapone (Ongentys): A New COMT Inhibitor for the Treatment of Parkinson's Disease.
St Onge E; Vanderhoof M; Miller S
Ann Pharmacother; 2021 Sep; 55(9):1159-1166. PubMed ID: 33233916
[TBL] [Abstract][Full Text] [Related]
15. Opicapone versus placebo in the treatment of Parkinson's disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial.
Chaudhuri KR; Odin P; Ferreira JJ; Antonini A; Rascol O; Kurtis MM; Storch A; Bannister K; Soares-da-Silva P; Costa R; Magalhães D; Rocha JF
BMC Neurol; 2022 Mar; 22(1):88. PubMed ID: 35279112
[TBL] [Abstract][Full Text] [Related]
16. Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease.
Rocha JF; Ferreira JJ; Falcão A; Santos A; Pinto R; Nunes T; Almeida L; Soares-da-Silva P
Clin Pharmacol Drug Dev; 2016 May; 5(3):232-40. PubMed ID: 27163503
[TBL] [Abstract][Full Text] [Related]
17. Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients.
Müller T; Schlegel E; Zingler S; Thiede HM
Cells; 2022 Apr; 11(9):. PubMed ID: 35563817
[TBL] [Abstract][Full Text] [Related]
18. Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine.
Fabbri M; Ferreira JJ; Lees A; Stocchi F; Poewe W; Tolosa E; Rascol O
Mov Disord; 2018 Oct; 33(10):1528-1539. PubMed ID: 30264443
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study.
Reichmann H; Lees A; Rocha JF; Magalhães D; Soares-da-Silva P;
Transl Neurodegener; 2020 Mar; 9(1):9. PubMed ID: 32345378
[TBL] [Abstract][Full Text] [Related]
20. OFF-times before, during, and after nighttime sleep periods in Parkinson's disease patients with motor fluctuations and the effects of opicapone: A post hoc analysis of diary data from BIPARK-1 and -2.
Hauser RA; Videnovic A; Soares-da-Silva P; Liang GS; Olson K; Jen E; Rocha JF; Klepitskaya O
Parkinsonism Relat Disord; 2024 Jun; 123():106971. PubMed ID: 38631081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
